Navigation Links
AtheroNova Announces Milestone Filing of IND in Russian Federation
Date:11/13/2012

IRVINE, Calif., Nov. 13, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that its Russian licensing partner OOO CardioNova has formally submitted its Investigational New Drug (IND) application with the Ministry of Health of the Russian Federation (Minzdrav).  This filing is the first step in the process of obtaining approval in Russia to conduct the Phase 1 human clinical trials in the centers selected by CardioNova.  It is expected that the approval of the application will be granted by the Ministry early in 2013 and the Phase 1 will commence shortly thereafter.

"We are extremely gratified in achieving this milestone in our path to human trials of AHRO-001," said AtheroNova CEO Thomas W. Gardner.  "OOO CardioNova has diligently pushed this filing forward with the utmost urgency and we want to thank them for their efforts to complete this major step in the process of clinical development of AHRO-001.  We continue to work aggressively toward our mutual goal of commencement of Phase 1 clinical trials within the next 90 days."

"We are pleased to have such a tremendous business partner in AtheroNova as we continue to endeavor toward approval of the Phase 1 protocol by the Ministry of Health," commented Dr. Alexey Eliseev, managing partner of Maxwell Biotech Group, OOO CardioNova's parent company. "Our objective is to work diligently with the Ministry of Healthcare for approval of our submission while making final preparations for the commencement of pre-screening and ultimately Phase 1 clinical trials in our Russian study centers.  We are excited with the prospect of initiating clinical trials in anticipation of potentially addressing one of the major health risks facing Russia, and throughout the world.

About AHRO-001

AHRO-001 is AtheroNov
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
2. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
3. Remedy Informatics Announces Growth Capital Investment from Merck Global Health Innovation Fund
4. RPS Announces Jonathan M. Fishbein, MD as Executive Vice President and Chief Medical Officer
5. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
6. Developmental Disabilities Software announces Safe Harbor Self-Certification Compliance
7. Hologic Announces Fourth Quarter and Fiscal 2012 Operating Results
8. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
9. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
10. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
11. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Electrocardiogram (ECG) Devices - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... US$330 million by 2016. The North America ... global market share while Europe ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ... 2012-2018"  report to their offering. Global Guidewires sector ... North America accounts for nearly ... Europe claims approximately 25% (2018). ...
(Date:12/15/2014)... NEW YORK and HERZLIYA PITUACH, Israel ... the "Company") (NASDAQ: IMNP ) announced today that ... of the Board succeeding Dr. Daniel Teper who ... been a member of Immune,s Board of Directors since 2013. ... comments: "I am delighted to represent the interest of shareholders ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... - Phase II Data Indicate Overall and Disease-Free ... Results from an adjuvant trial in,high-risk melanoma patients ... (sargramostim) achieved disease-free and/or overall,survival. These findings, which ... at the 44th annual meeting of the American ...
... SUNNYVALE, Calif., June 5 Pharmacyclics, Inc.,(Nasdaq: ... from a Phase 1/2 study showing a,46 ... multiply recurrent,non-Hodgkin,s lymphoma (NHL) who were treated ... Yttrium-90 Ibritumomab Tiuxetan,(Zevalin(TM)), an approved antibody-targeted radiation ...
Cached Medicine Technology:Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 2Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 3Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 4Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 5Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma 2Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma 3Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma 4
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... holiday party season fast approaching, a new study reveals that ... arrests have fewer drunk drivers on their roads. The ... vigilantly are better able to deter inebriated revelers from getting ... new laws are being passed regarding drinking and driving," said ...
(Date:12/15/2014)... Cancer researchers have just published an important new ... malignant pleural mesothelioma. Surviving Mesothelioma has just posted an ... here to read it now. , Doctors at ... New York’s Langone Medical Center performed complete genetic analyses ... an effort to pinpoint the genes that are most ...
(Date:12/15/2014)... SIMpalm, a leading mobile app development ... for its client, which allows users to keep track ... in finding the right wine. At the center ... sensory, chemistry and wine information. All this information is ... Those wines that are close counterparts to one another ...
(Date:12/15/2014)... -- Expert pilots process visual information more efficiently than ... decisions during landings, a new study shows. Landing ... to master, and 36 percent of all airplane crashes ... approach and landing. Researchers monitored the brain activity ... while they were at the controls of a flight ...
(Date:12/15/2014)... OR (PRWEB) December 15, 2014 ... seeks to bring attention to restrictive state laws ... position paper on this important area of public ... Laws Can Compromise the Integrity of Independent Review, ... and access of independent peer review determinations can ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... economy, the Rs 3,200-crore Indian health insurance industry is poised ... a growth rate of over 44 per cent per annum, ... insurers and even life insurers are jumping in the fray. ... instance, is planning to launch a health insurance product ...
... reportedly annoyed, for her upcoming tour bosses have asked her to ... is over . ,According to a source, although the ... was bugged by the contract as no other band member was ... requirement really, Geri isnt planning to get pregnant but she was ...
... snide remarks about her, claiming that the actress is too old ... Kutcher tied the knot in September 2005, and the actress became ... Guynes, who is separated from Moores half-brother commented that the 44-year-old ... was old. ,I think Demi is getting too old ...
... nanny for not turning up on time and lying to her ... her about visiting her dad in Wales, while she was actually ... care of her son Harvey as the nanny did not turn ... was criticized by Chris Moyles. ,Jordan went straight to ...
... with two felony counts of possession of a controlled substance, ... prescription and possession of marijuana, and a speeding infraction ... July 4. ,A law enforcement source revealed ... prescription drugs had been recovered from Albert Gore Thirds car. ...
... men are not influenced by advertisements that show horrific ... them, says a report . ,The ... dreadful consequences of drink-driving can influence young men not ... such public announcements show that a minimum penalty of ...
Cached Medicine News:Health News:Life Insurers in India to Launch Health Insurance Policies 2Health News:Drink-drivers Not Influenced by Ads Unless It Affects Them Personally 2
Inquire...
Inquire...
Inquire...
... range of 18 Ophthalmic frames created ... producted to the very hightest quality. ... lightweight Titanium and Beta Titanium models, ... of beautifully formed and innovative designs ...
Medicine Products: